Can nattokinase lower blood pressure?

High blood pressure - or hypertension - is one of the most prevalent and dangerous chronic conditions in the world, affecting an estimated 1.28 billion adults globally according to the World Health Organization. It is often called the "silent killer" because it causes no obvious symptoms while steadily damaging the heart, arteries, kidneys, and brain.

Against this backdrop, researchers and supplement formulators have turned increasing attention to a remarkable enzyme derived from a traditional Japanese fermented soybean dish called natto: nattokinase enzyme. Originally discovered in 1987 by Dr. Hiroyuki Sumi at the University of Chicago, nattokinase has since accumulated a compelling body of clinical evidence suggesting it may play a meaningful role in cardiovascular health - including, critically, blood pressure regulation.

So can nattokinase actually lower blood pressure? The short answer is: the evidence is genuinely promising. But the full picture is more nuanced, and understanding it properly is essential for supplement brands, formulators, and health-conscious consumers alike. Let's unpack the science, the mechanisms, the clinical data, and the practical applications - step by step.

What Is Nattokinase Enzyme?

Nattokinase (subtilisin NAT, EC 3.4.21.62) is a serine protease enzyme produced during the fermentation of soybeans by the bacterium Bacillus subtilis var. natto. It is the primary bioactive compound responsible for the unique health properties associated with natto, a staple of traditional Japanese cuisine that has been consumed for over a thousand years.

What makes nattokinase scientifically exceptional is its fibrinolytic activity - its ability to break down fibrin, the protein that forms the structural matrix of blood clots. This property, first identified by Dr. Sumi when he observed natto dissolving a fibrin clot on a laboratory plate, has since been confirmed and expanded upon in numerous in vitro, animal, and human clinical studies.

How Is Nattokinase Produced for Supplements?

For commercial supplement applications, nattokinase is produced through controlled fermentation of Bacillus subtilis natto, then extracted, purified, and standardized - typically measured in Fibrinolytic Units (FU) or Nattokinase Units (NKU). The standardization of enzyme activity is critical for consistent dosing and clinical reproducibility.

Common commercial specifications include:

* 2,000 FU/g - standard grade for general cardiovascular formulas

* 5,000 FU/g - concentrated grade for targeted therapeutic applications

* 20,000 FU/g - high-potency extract for clinical-dose supplement products

The Mechanisms: How Could Nattokinase Lower Blood Pressure?

Understanding how nattokinase enzyme may reduce blood pressure requires a brief look at the multiple biological pathways through which it operates. This is not a single-mechanism ingredient - it works through several complementary pathways simultaneously.

1. Fibrinolytic Activity: Dissolving Clots and Improving Blood Flow

The most well-documented mechanism is nattokinase's direct fibrinolytic action. By degrading fibrin in blood clots and thrombi, nattokinase reduces blood viscosity and improves circulation. Reduced blood viscosity directly lowers the resistance against which the heart must pump - contributing to lower blood pressure readings.

Research published in PMC (National Institutes of Health) confirms that nattokinase has potent fibrinolytic activity alongside antihypertensive, anti-atherosclerotic, and lipid-lowering properties - a multi-targeted cardiovascular profile that few single ingredients can match.

2. ACE Inhibition: A Direct Antihypertensive Mechanism

Perhaps the most direct blood-pressure-relevant mechanism is nattokinase's ability to inhibit Angiotensin-Converting Enzyme (ACE). ACE is the enzyme responsible for converting angiotensin I to angiotensin II - a potent vasoconstrictor that raises blood pressure. Many pharmaceutical antihypertensive drugs (ACE inhibitors like lisinopril and enalapril) work through exactly this mechanism.

Nattokinase enzyme has been shown to generate peptide fragments during its activity that exhibit ACE-inhibitory properties, effectively mimicking - through natural means - the mechanism of a major class of blood pressure medications.

3. Degradation of Angiotensin II

Beyond inhibiting ACE, nattokinase has also been shown to directly degrade angiotensin II itself - the vasoconstrictor - further reducing its vasopressive effects. This dual action (inhibiting production AND degrading the active molecule) makes nattokinase's antihypertensive mechanism particularly robust.

4. Antiplatelet Activity & Improved Microcirculation

Nattokinase inhibits platelet aggregation, reducing the tendency of blood to clot and improving microcirculation throughout the vascular system. Improved peripheral circulation reduces total peripheral vascular resistance - a key determinant of blood pressure.

5. Anti-Atherosclerotic Effects

Atherosclerosis - the buildup of plaques in arterial walls - is a major driver of elevated blood pressure by reducing arterial compliance (flexibility). Research in ScienceDirect confirms that nattokinase exhibits anti-atherosclerotic activity, potentially by degrading fibrin components within plaques and modulating lipid metabolism-associated enzymes.

What Does the Clinical Evidence Show?

Mechanistic plausibility is important, but clinical evidence is what truly matters. Here's what the human trials actually demonstrate:

The Landmark Kim et al. Randomized Controlled Trial (2008)

One of the most cited studies on nattokinase and blood pressure is the randomized, double-blind, placebo-controlled trial by Kim et al. (2008), published in Hypertension Research. In this study, 86 participants with pre-hypertension or stage 1 hypertension received either 2,000 FU of nattokinase daily or a placebo for 8 weeks.

The results were clinically meaningful:

* Systolic blood pressure decreased by an average of 5.55 mmHg in the nattokinase group

* Diastolic blood pressure decreased by an average of 2.84 mmHg

* The renin activity - a key marker of the renin-angiotensin system driving blood pressure - was significantly reduced

The authors concluded that "increased intake of nattokinase may play an important role in preventing and treating hypertension."

The 2024 Meta-Analysis: 607 Participants

A comprehensive meta-analysis and systematic review published in PMC (2024) pooled data from multiple clinical trials involving 607 participants to assess nattokinase's effects on cardiovascular risk factors, including blood pressure.

The findings confirmed that nattokinase supplementation showed a beneficial influence on blood pressure, though the authors noted that effect sizes varied across studies and called for larger, longer-duration trials to establish definitive clinical guidelines. Importantly, no significant safety concerns were identified across the pooled participant population - a reassuring signal for supplement formulators.

The 2024 Frontiers in Nutrition RCT

A 90-day randomized, double-blind, placebo-controlled trial published in Frontiers in Nutrition (2024) investigated the effects of nattokinase (NK) and red yeast rice (RYR) supplementation on cardiometabolic parameters in patients with stable cardiovascular risk profiles.

The study demonstrated measurable improvements in cardiometabolic markers in the nattokinase group, reinforcing the ingredient's role as a functional cardiovascular supplement - and specifically highlighting its potential in combination formulas targeting multiple cardiovascular risk factors simultaneously.

Springer Nature Review (2025): Fibrinolytic Enzymes in Cardiovascular Management

A 2025 review published in Springer Nature examined the therapeutic potential of fibrinolytic enzymes - with nattokinase as the primary focus - in managing cardiovascular disease. The review characterized nattokinase as "pivotal in managing cardiovascular disease" and a "natural adjunct in treating circulatory conditions", noting its multi-mechanism action and favorable safety profile compared to pharmaceutical thrombolytics.

Nattokinase vs. Pharmaceutical Antihypertensives: An Important Distinction

It is essential - both scientifically and from a regulatory compliance standpoint - to clearly position nattokinase within the supplement landscape rather than as a pharmaceutical replacement.

The key takeaway: Nattokinase is not a replacement for prescribed antihypertensive medications. It is a scientifically supported dietary supplement ingredient with a meaningful role in cardiovascular wellness, blood pressure support, and preventive health strategies - particularly for individuals with pre-hypertension or those seeking complementary support alongside lifestyle modifications.

Beyond Blood Pressure: The Full Cardiovascular Profile of Nattokinase Enzyme

While blood pressure is the most searched-for benefit, nattokinase's cardiovascular utility extends considerably further - making it one of the most comprehensive single-ingredient cardiovascular supplement actives available.

Thrombosis Prevention & Stroke Risk Reduction

By maintaining fibrinolytic balance and reducing platelet aggregation, nattokinase supports healthy blood flow and reduces the risk of pathological clot formation - a primary driver of heart attacks and ischemic strokes.

Atherosclerosis Management

Nattokinase's ability to degrade fibrin components within arterial plaques and modulate lipid metabolism makes it relevant in atherosclerosis prevention and management - a benefit that extends well beyond blood pressure alone.

Cognitive Health & Cerebrovascular Protection

Emerging research suggests nattokinase may support cerebrovascular health by improving blood flow to the brain and reducing the risk of small vessel disease - an area of growing interest given the global burden of vascular dementia and cognitive decline.

Synergistic Formulation Potential

Nattokinase combines powerfully with complementary cardiovascular ingredients:

* Serrapeptase - another fibrinolytic enzyme for enhanced systemic enzyme activity

* CoQ10 - mitochondrial energy support for cardiac muscle

* Omega-3 fatty acids - anti-inflammatory and triglyceride-lowering

* Magnesium - vasodilation and blood pressure support

* Berberine - metabolic and cardiovascular health

* Red yeast rice - lipid management (as demonstrated in the 2024 Frontiers in Nutrition trial)

Who Is Nattokinase Enzyme For? Target Consumer Profiles

Understanding the target consumer is essential for effective product positioning. Nattokinase is most relevant for:

1. Adults with Pre-Hypertension (120–139/80–89 mmHg)

This is the sweet spot for nattokinase supplementation - individuals whose blood pressure is elevated but not yet at the threshold requiring pharmaceutical intervention. The 5–6 mmHg systolic reduction demonstrated in clinical trials is clinically meaningful at this level.

2. Cardiovascular Health-Conscious Adults (45+)

As arterial stiffness and atherosclerotic risk increase with age, nattokinase's multi-mechanism cardiovascular support becomes increasingly relevant. This demographic is also the most proactive about supplement use.

3. Individuals Seeking Pharmaceutical Adjunct Support

Some individuals on antihypertensive medications seek complementary natural support. Note: Any combination with blood-thinning medications requires physician supervision due to additive anticoagulant effects.

4. Athletes & Active Adults

Improved circulation, reduced blood viscosity, and enhanced oxygen delivery make nattokinase relevant in sports nutrition contexts - particularly for endurance athletes and those focused on cardiovascular conditioning.

5. Metabolic Syndrome & Diabetes Risk Populations

Given nattokinase's effects on fibrinolysis, platelet aggregation, and lipid metabolism, it is increasingly relevant in formulas targeting metabolic syndrome - a cluster of conditions that dramatically elevates cardiovascular risk.

Formulation Considerations for Supplement Brands

For brands and formulators working with nattokinase enzyme, several technical considerations are critical:

Dosage

Based on clinical evidence, effective doses range from:

* 2,000 FU/day - minimum effective dose for blood pressure and cardiovascular support

* 3,000–5,000 FU/day - optimal range for most cardiovascular formulas

* Up to 10,000 FU/day - used in some intensive cardiovascular support protocols

Enteric Coating

Nattokinase is a protein-based enzyme and is susceptible to degradation by stomach acid. Enteric-coated capsules are strongly recommended to ensure the enzyme reaches the small intestine intact and is absorbed effectively.

Stability Considerations

Store at cool, dry conditions (below 25°C) to preserve enzyme activity

Avoid formulating with strong oxidizing agents

Moisture is the primary enemy of enzyme stability - use desiccant packaging

Vitamin K2 Considerations

Traditional natto contains high levels of Vitamin K2 (MK-7), which has anticoagulant interactions. Commercial nattokinase supplements are typically processed to remove Vitamin K2, making them safe for broader populations - but formulators should verify this specification with their supplier.

Safety & Contraindications

Nattokinase has a strong clinical safety profile. However, due to its anticoagulant and fibrinolytic activity:

* Contraindicated in individuals taking warfarin or other anticoagulant medications without physician supervision

* Caution advised before surgical procedures

* Not recommended during pregnancy without medical guidance

What to Look for in a Quality Nattokinase Enzyme Supplier

The quality of nattokinase varies significantly between suppliers. Here's a practical checklist for procurement:

A reputable supplier will provide a comprehensive Certificate of Analysis (CoA) for every batch, with third-party laboratory verification of enzyme activity - not just manufacturer self-reporting.

The Market Opportunity: Why Nattokinase Is a Smart Ingredient Investment

The global cardiovascular supplement market is projected to exceed $15 billion by 2028, driven by aging populations, rising hypertension prevalence, and growing consumer preference for natural, evidence-based health solutions. Within this market, nattokinase enzyme occupies a uniquely compelling position:

✅ Strong clinical evidence - multiple RCTs and a 2024 meta-analysis supporting blood pressure benefits

✅ Multi-mechanism action - fibrinolysis, ACE inhibition, antiplatelet, anti-atherosclerotic

✅ Consumer recognition - growing awareness driven by mainstream health media and longevity communities

✅ Clean-label friendly - natural fermentation origin, non-GMO options available

✅ Formulation versatility - capsules, tablets, softgels, combination cardiovascular formulas

✅ Differentiation potential - allows brands to move beyond basic fish oil and CoQ10 into more sophisticated cardiovascular positioning

For supplement brands looking to build credible, science-backed cardiovascular product lines, nattokinase is one of the highest-value ingredients available today.

JOYWIN Natural: Your Trusted Source for Nattokinase Enzyme

At JOYWIN Natural (www.joywinnatural.com), we supply pharmaceutical-grade nattokinase to dietary supplement brands, contract manufacturers, and nutraceutical formulators worldwide.

Our nattokinase offering includes:

* Multiple activity grades - 2,000 FU/g, 5,000 FU/g, 20,000 FU/g to match your formulation requirements

* Full documentation - Certificate of Analysis, MSDS, third-party enzyme activity verification, heavy metals and microbial testing

* Vitamin K2-free - confirmed low K2 content for broad consumer safety

* Global certifications - Kosher, Halal, Non-GMO verified

* Flexible MOQ - supporting both emerging brands and large-scale manufacturers

* Technical support - formulation guidance, dosage recommendations, and regulatory documentation assistance

JOYWIN's commitment to rigorous quality control, transparent supply chains, and responsive technical support means you receive not just an ingredient - but a formulation partnership built on scientific integrity.

Conclusion: The Evidence Is In - Nattokinase Enzyme Deserves a Place in Cardiovascular Formulas

So, can nattokinase lower blood pressure? Based on the current body of evidence, the answer is a well-supported yes - with important context.

Clinical trials demonstrate a meaningful reduction in both systolic and diastolic blood pressure at doses of 2,000 FU per day, operating through multiple complementary mechanisms including ACE inhibition, fibrinolysis, and angiotensin II degradation. A 2024 meta-analysis of 607 participants confirmed these benefits while establishing a reassuring safety profile. Mechanistic research continues to expand our understanding of how this remarkable enzyme supports the entire cardiovascular system - from arterial plaque management to cerebrovascular protection.

For supplement brands, the opportunity is clear: nattokinase is a scientifically credible, commercially compelling, and formulation-versatile ingredient that addresses one of the world's most pressing health challenges. In a market crowded with underdifferentiated cardiovascular products, nattokinase offers a genuine opportunity to build products that are both evidence-based and consumer-relevant.

The science has spoken. The market is ready. The question now is whether your next formula will include it.

JOYWIN founded in 2013 is an innovation-driven biotechnology company. We provide the manufacture of plant extracts, plant proteases, and customized products. If you want to know more about  Nattokinase Enzyme  or are interested in purchasing it, you can send an email to contact@joywinworld.com. We will reply to you as soon as possible after we see the message.